The possible involvement of interleukin-6 in congestive heart failure in a postmenopausal woman with uterine fibromatosis

Interleukin-6 (IL-6) has been shown to contribute to the progression of myocardial damage and dysfunction in congestive heart failure. We report a case of a 53-year old woman with congestive heart failure that may have been caused by IL-6 secreting uterine leiomyoma. The woman developed progressive...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Ohta (Author), N. Keira (Author), S. Yoshida (Author), R. Yasuda (Author), Y. Tarumi (Author), H. Tsuchiya (Author), M. Kikai (Author), T. Nomura (Author), T. Tatsumi (Author)
Format: Book
Published: IMR Press, 2020-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin-6 (IL-6) has been shown to contribute to the progression of myocardial damage and dysfunction in congestive heart failure. We report a case of a 53-year old woman with congestive heart failure that may have been caused by IL-6 secreting uterine leiomyoma. The woman developed progressive dyspnea, pleural effusion, and leg edema with a decreased left ventricular ejection fraction (LVEF). Imaging studies indicated uterine leiomyoma compressing the vena cava. Due to unresponsiveness to conventional medical treatment, she underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy to alleviate compression of the vena cava. After surgery, pleural effusion and leg edema completely resolved. Concomitant with the subsequent improvement of LVEF, a pre-operative serum IL-6 measurement of 36.2 pg/mL fell to 1.6 pg/mL postoperatively. Immunologically positive staining for IL-6 was demonstrated in the cytoplasm of most of the uterine leiomyoma cells. These findings suggest that IL-6 produced by leiomyoma cells may have been involved in the pathophysiological progression of heart failure and associated hemodynamic changes.
Item Description:0390-6663
10.31083/j.ceog.2020.04.5062